An observational study in Catheter Obstruction, Catheterization, Peripheral and Phlebitis, sponsored by Consorci Sanitari de l'Alt Penedès i Garraf. Not yet recruiting at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Consorci Sanitari de l'Alt Penedès i Garraf · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to learn whether locking peripheral venous catheters with heparin keeps them open (patent) better than locking them with saline, in adults admitted to hospital who have a peripheral venous catheter for intermittent treatment. The main questions it aims to answer are:
Researchers will compare patients admitted to a hospital that routinely locks catheters with saline with patients admitted to a hospital that routinely locks catheters with heparin.
Maintaining the patency of peripheral venous catheters (PVCs) used intermittently is a relevant and unresolved clinical question. Reference care bundles such as Bacteremia Zero and Phlebitis Zero do not explicitly address whether catheters should be locked with saline or heparin, and the evidence comparing both options, especially taking into account the interval between infusions, is limited.
The two hospitals of the Consorci Sanitari de l'Alt Penedès i Garraf offer a natural experiment: Hospital Residència Sant Camil systematically locks PVCs with sodium heparin 20 IU/mL , while Hospital Comarcal de l'Alt Penedès locks them with sterile 0.9% saline. Allocation to each cohort is determined solely by the hospital of admission. Data for the year before the start of the study will be extracted retrospectively from the electronic medical record, where nurses record the status of the catheter and the reason for removal or replacement on each shift.
The primary analysis will compare, with a superiority approach, the percentage of blocked catheters between cohorts, considering only the first catheter inserted in each patient. Logistic regression will adjust for confounders that are unbalanced between cohorts or clinically relevant (age, sex, type and schedule of intravenous medication, anticoagulation, and coagulation disorders). Sensitivity analyses will include all catheters per patient (mixed models or generalized estimating equations) and will exclude patients at particularly high risk of blockage. Assuming an absolute difference of 3% between cohorts, alpha 5%, power 80%, and 5% losses, 1,725 patients per cohort (3,450 in total) are needed. Data analysts will be blinded to the cohort during the primary analysis.
47 studies on the registry are indexed under Phlebitis; 10 are open to participants now.
Browse Phlebitis studies →Consorci Sanitari de l'Alt Penedès i Garraf is the lead sponsor of 45 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All adults admitted to Hospital Residència Sant Camil or Hospital Comarcal de l'Alt Penedès (both hospital belonging to CSAPG) during the study period who had at least one peripheral venous catheter inserted for intermittent treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Percentage of blocked peripheral venous catheters
Percentage of patients whose first peripheral venous catheter was removed or replaced because of blockage (occlusion).
Time frame: Hospital discharge, up to 12 weeks
Plan to share: Yes — IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).
Supporting information: Study protocol
Time frame: After publication of main results of the study.
Access criteria: IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Consorci Sanitari de l'Alt Penedès i Garraf